Santen gets China review for myopia drug: Santen stock gains 1.60 percent

Published on 10/06/2026 at 10:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 0.30 percent to JPY 68.96 billion in the first quarter. Santen stock costs EUR 9.53 on October 6, 2026 after EUR 9.38.

Santen, JP3336000009, Illustration mit AI erstellt.

Santen (ISIN JP3336000009) said on September 14, 2026 that China's Center for Drug Evaluation accepted its application for a 0.025% atropine solution to slow myopia progression, according to MarketScreener. Santen stock was trading at EUR 9.53 at Lang & Schwarz, up 1.60 percent from the EUR 9.38 prior close.

China review expands the pipeline

The candidate, STN1012700, is a preservative-free, single-use ophthalmic solution designed to suppress ocular axial elongation in children. In Japan, Santen markets the product as Ryjusea, and the Chinese filing gives the company a regulatory milestone in one of the largest markets for childhood myopia, MarketScreener reported.

The filing is a review acceptance rather than a marketing approval, so the next value inflection remains tied to the Chinese regulatory process. That distinction matters because the product is still an expansion option, not yet a new sales contributor in China.

First-quarter figures point to growth

For the three months ended June 30, 2026, revenue rose 0.30 percent year over year to JPY 68.96 billion, while core operating profit increased 9.30 percent to JPY 10.60 billion, according to Quartr. Net profit attributable to owners rose 22.40 percent to JPY 7.20 billion, and gross profit margin improved to 58.00 percent from 54.00 percent.

Santen maintained its fiscal-year revenue forecast of JPY 311.00 billion, representing 6.60 percent growth, and kept its core operating profit forecast at JPY 59.00 billion, up 7.00 percent, Quartr said. The next earnings date shown for Santen is November 5, 2026, giving investors a defined checkpoint for progress against the second-half-weighted plan.

Analyst context remains constructive but comes with a wide valuation gap. Investing.com lists nine analysts, including JPMorgan with a JPY 2,800.00 target dated August 31, 2026, unchanged from JPY 2,600.00; its average target is JPY 2,377.78. Against the Tokyo quote of JPY 1,683.50, that average target is 41.25 percent higher.

Santen stock trades higher in Europe

Santen stock was trading at EUR 9.53 at Lang & Schwarz on October 6, 2026 at 10:00 a.m. CEST, plus 1.60 percent versus the prior close of EUR 9.38. On the Tokyo Stock Exchange, the stock was last at JPY 1,683.50 on October 6, 2026 at 3:30 p.m. JST; its 52-week range was JPY 1,458.00 to JPY 2,254.00 and its market capitalization was JPY 541.6 billion.